08/02/2023 Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
NRThe Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusion on the MOH List of Subsidised Drugs for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, because it does not represent a cost-effective use of healthcare resources at the price proposed by the company.